55 results about "Recombinant Human Endostatin" patented technology

The invention belongs to the field of bio-pharmaceutical products, which provides a chemical modification method for recombinate human rh-Endostatin ('rh-ES' is called for short) through the way of using mPEG-propionaldehyde to be combined on the fixed point of free amino of N-terminal amino acid of rh-ES. Mono-PEG-rhES is the output material, its purity meet the requirements of biological products. It plays a key role in the hydrolysis resistance of trypsin and chymotrypsin, it can be used as long-acting formulations for its stability for pH and temperature and there is a great perspective in the clinical treatment of cancer.

The invention belongs to the technical field of biological products and discloses a medicinal composition and application thereof. The composition takes recombinant human endostatin and hexadecadrol as effective constituents, wherein the mole ratio of the recombinant human endostatin to the hexadecadrol is 10-100:1. The recombinant human endostatin in the combination can co-act with the hexadecadrol to restrain the multiplication, invasion, migration and angiogenesis of endothelial cells. An in-vivo test result proves that the recombinant human endostatin and the hexadecadrol co-act with each other to restrain the growth of the mice H22 transplanted liver tumor and human Bel7402 transplanted liver tumor. Therefore, the composition can be widely applied to medicaments for treating liver cancer.

A cationic liposome is proportionally prepared from DOPE, DOTMA and cholesterol and can be used to encapsulate the object (adenovirus carrier) to obtain a recombinant human endostatin adenovirus-cationic liposome composition carrying the active antineoplastic genes for suppressing the growth of tumor. Its preparing process is also disclosed.

The invention discloses a recombinant human endostatin protein with different amino acid structures, a method for preparing the recombinant human endostatin protein and application thereof. Amino acid sequences of a recombinant human endostatin protein 1 are shown as SEQ ID NO.1, and amino acid sequences of a recombinant human endostatin protein 2 are shown as SEQ ID NO.2. The recombinant human endostatin protein, the method and the application have the advantages that the two types of recombinant proteins are active in the aspects of inhibiting the proliferation activity of vascular endothelial cells under the induction actions of basic fibroblast growth factors (bFGF) and inhibiting the angiogenesis activity of chick chorioallantoic membranes (CAM) and are easy to enter the vascular endothelial cells and vascular endothelial cells of the chick chorioallantoic membranes, and transmembrane effects of the recombinant human endostatin protein and the structural stability of N ends can be obviously improved; effects of directly inhibiting tumor cell growth can be realized, effects of inhibiting generation of neonatal vascular endothelial cells can be effectively realized, and the recombinant human endostatin protein can be used for treating various diseases, including solid tumor, retinal diseases due to diabetes mellitus and rheumatoid arthritis, due to angiogenesis.

The invention relates to a method for preparing recombinant human endostatin chitosan nanoparticles for injection, in particular to the preparation of the recombinant human endostatin chitosan nanoparticles by taking biodegradable chitosan as a carrier and sodium tripolyphosphate as an ion crosslinking agent and performing an ion crosslinking reaction on chitosan solution of recombinant human endostatin and the solution of sodium tripolyphosphate under a continuously stirring condition.

The invention generally relates to compositions of and methods for production of recombinant adenoviruses that carry therapeutic genes. More particularly, the invention relates to lyophilized recombinant adenoviruses injection and its related production procedures, including production procedures for the recombinant adenovirus vectors (or other viral vectors) that carry the genes of human endostatins.

The invention relates to a recombinant human endostatin temperature-sensitive gel composition for injection can release medicaments slowly and stably through one time of medicament administration, so the medicament administration times are reduced, physiological pain in patients is relieved and the clinical compliance of the patients is improved.

The present invention is quantitative measurement method of extracorporeal activity of high activity soluble recombinant human endostatin produced through a genetic engineering process, and features that in the test, the vascular endothelial cell with introduced bFGF and/or VEGF gene and without need of adding additional bFGF or VEGF for excitation is added directly into the measured sample to calculate the activity quantitatively. The method is simple and accurate, and may be applied in industrial production and clinical angiogenesis antagonizing treatment.

The invention discloses fusion protein composed of Her2 nano antibody dipolymer and recombinant human endostatin as well as a preparation method and application thereof. The recombinant human endostatin fusion protein comprises the Her2 nanobody dipolymer and recombinant human endostatin protein, and the fusion protein is easy to purify, can specifically target to breast cancer cells with high expression of Her2, has good transmembrane effect and can effectively inhibit the growth of tumor cells. The invention discloses the application of the recombinant human endostatin fusion protein in preparing a medicine for detecting or treating breast cancer in a targeting mode clinically, the concentration of the medicine in the location of tumor lesion can be increased, and correspondingly the dose-effect ratio is increased. The invention also discloses the recombinant expression vectors, transgenic cell lines or transgenic recombinant bacteria of the encoding gene of the recombinant human endostatin fusion protein as well as a gene engineering preparation method to be applied in clinical production and preparation of the fusion protein.

The invention discloses an induced expression method of recombinant human endostatin. The method comprises the following steps: fermenting engineering bacteria until the OD600 value of fermentation liquor is 10-15, adding an inducer isopropyl-beta-d-thiogalactoside (IPTG), a carbon source substance and a nitrogen source substance, so that the concentration of the IPTG in the fermentation liquor is 0.2-0.4mmol/L; cultivating at 30-37 DE C for 2.5-3.5 hours; adding the inducer IPTG, so that the concentration of the IPTG in the fermentation liquor is 0.1-0.3mmol/L, and continuing to cultivate for 3-5 hours. By adopting the induced expression method of the recombinant human endostatin disclosed y the invention, the requirements of large-scale production of the recombinant human endostatin can be met, and efficient induced expression is achieved at high cell concentration.

The invention discloses a recombinant human endostatin liposome microbubble, which is prepared by a method in the following steps: dispersing DSPE-PEG (distearoyl phosphoethanolamine-polyethylene glycol) 2000-Biotin and DSPC (disaturated phosphatidylcholine) in a molar ratio of 1:(0.5-4) in a phosphate buffer; introducing inert gas, mechanically oscillating, adding streptavidin, and incubating at room temperature, wherein the molar ratio of the streptavidin to the DSPE-PEG2000-Biotin is 1:(1-2); and adding biotinylated recombinant human endostatin, and incubating at room temperature to prepare the recombinant human endostatin liposome microbubble, wherein the molar ratio of the streptavidin to the biotinylated recombinant human endostatin is 1:(1-2). The invention also discloses application of the recombinant human endostatin liposome microbubble in preparing a medicament for inhibiting tumor angiogenesis under ultrasound mediation. The recombinant human endostatin liposome microbubble has a tumor inhibition rate of 41.3 percent, which is remarkably superior to the inhibition effect of a single recombinant human endostatin liposome microbubble.

The invention relates to a recombinant human endostatin nanoparticle composition for injection and a preparation method thereof. The recombinant human endostatin nanoparticle composition can be prepared by methods such as a covalent bond linking method and an ionic induction method and by using biologically degradable polymer as a carrier. The recombinant human endostatin nanoparticle composition can be prepared into injection and freeze-dried powder injection, has high medicament carrying capacity and uniform particle size distribution, is suitable for intravenous injection and can delay the release of recombinant human endostatin.

A process for producing soluble bioactive recombinant human endothelium inhibin in colibacillus and separating and purifying it is disclosed. The resultant recombinant human endothelium inhibin can specifically and dosage-dependently suppress the reproduction of endothelium cells and the generation of new blood vessel.

The invention relates to a refolding solution of recombinant human endostatin. The refolding solution comprises the following components: guanidine hydrochloride, reduced glutathione, oxidized glutathione and a complexing agent and the pH value of the refolding solution is 4.0-5.0. The invention also provides a preparation and application methods of the refolding solution of recombinant human endostatin. By virtue of the refolding solution of recombinant human endostatin disclosed by the invention, the high refolding yield of recombinant human endostatin can be realized, thereby ensuring the mass production of the recombinant human endostatin.